Sharp Mesa Vista Clinical Research Center
Sharp Mesa Vista Alzheimer's Clinical Trials
Sharp Mesa Vista Hospital is enrolling both men and women ages 55 to 85 for studies of investigational medicines for Alzheimer's disease. To qualify, you must:
- Attend study visits at Sharp Mesa Vista Hospital's Clinical Research Center
- Have a caregiver (spouse, relative or health care aide) who can accompany you to study visits and help monitor your study progress
Clinical trial for individuals at high risk for Alzheimer's.
EARLY-AD — this study is designed for individuals who are currently not experiencing symptoms of memory loss, but are at a high risk for Alzheimer's disease due to age and/or genetics (such as having a first-degree relative with Alzheimer's disease). The study is looking at the efficacy and safety of an oral investigational drug in slowing cognitive decline. Participation in the study will last about four and a half years to carefully monitor cognitive and memory functioning.
Mild cognitive impairment clinical trials.
MISSION-AD — this study is designed for individuals with early Alzheimer's disease or mild cognitive impairment. The study is investigating the efficacy and safety of an oral investigational drug on symptoms of Alzheimer's disease. Study participation lasts approximately two years.
CREAD2 — this study is designed for individuals with early Alzheimer's disease or mild cognitive impairment. The study asks what effect an investigational drug will have on symptoms of Alzheimer's disease over the course of approximately two years. The investigational drug being studied is in the form of an infusion that participants receive at Sharp Mesa Vista periodically.
Mild Alzheimer's clinical trials.
NAVIGATE-AD — a study for people who have been experiencing worsening memory problems, or who may have been diagnosed with mild Alzheimer’s disease. As Alzheimer’s disease progresses, a protein called amyloid-beta builds up inside the brain. The NAVIGATE-AD study will ask what effect an oral investigational study drug has on the protein build up and on clinical symptoms of Alzheimer’s disease. Learn more about this study.
DAYBREAK-ALZ — the study is also for individuals who have been experiencing worsening memory problems or who have been diagnosed with mild Alzheimer's disease. The oral investigational drug will contain either a lower dose of the study drug, a higher dose of the study drug, or a placebo, depending on which group you are assigned to. Learn more about this study.
ReCOGNITION — this study is for people currently taking medication to treat mild Alzheimer's disease. Study will last for six months, and participants will receive one of three doses of either the study drug (Piromelatine) or a placebo. Participants will continue taking their prescribed medication during the study. The study will determine if Piromelatine will improve slow wave sleep and, additionally, will also improve memory and limit the effects of Alzheimer's. Learn more about this study.
How to enroll.
Choose the best doctor in San Diego for you.
View doctors in San Diego.
"Patients are satisfied when they receive top-quality care for a broad range of medical problems."
"I use evidence-based treatments to promote the accurate diagnosis, well-being and recovery for children and adolescents."
""The secret of caring for the patient is to care for the patient." — William Osler"
"Each patient's experience is very important and I strive to meet individual needs while delivering the highest quality of care."
"I strive to instill in each of my patients a will to heal and a confidence in themselves."
"My goal is to serve the family's medical needs with an emphasis on keeping everyone healthy."